Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells 15,741 Shares of Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Sherry Korczynski sold 15,741 shares of Aquestive Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $65,639.97. Following the sale, the insider directly owned 241,117 shares of the company’s stock, valued at approximately $1,005,457.89. This trade represents a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Aquestive Therapeutics Trading Up 2.5%

Shares of AQST stock traded up $0.11 on Wednesday, reaching $4.31. 1,170,828 shares of the stock were exchanged, compared to its average volume of 5,614,740. The company has a market capitalization of $525.38 million, a price-to-earnings ratio of -5.52 and a beta of 1.61. The business’s 50 day moving average price is $4.13 and its 200 day moving average price is $5.22. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The business had revenue of $13.02 million during the quarter, compared to the consensus estimate of $13.28 million. Equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AQST shares. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Lake Street Capital set a $6.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $8.80.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets grew its stake in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares during the last quarter. Modern Wealth Management LLC acquired a new position in Aquestive Therapeutics during the second quarter worth approximately $33,000. Cox Capital Mgt LLC acquired a new position in Aquestive Therapeutics during the third quarter worth approximately $59,000. Finally, Kestra Private Wealth Services LLC purchased a new stake in Aquestive Therapeutics in the third quarter valued at approximately $60,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.